RWE / Unlocking the Full Potential of Cell & Gene
Emerging cell and gene therapies herald immense clinical value for patients, society, and healthcare systems:…
Cell & Gene Therapy
Cell & Gene Therapy / Collaborative Spirit
One of the more intriguing aspects about the new wave of cell and gene therapies (CGT) coming onstream is that they are not just technologically innovative in terms of the…
USA / Navigating Increasingly Stormy Market Access Waters
Certara’s Ulrich Neumann examines some of the major US market access trends of the past few years, including…
Cell & Gene Therapy / Reconsidering Manufacturing
Advances in cell and gene therapies (CGT) are credited with thoroughly transforming medicinal science and creating…
In Conversation
Ken-ichiro Hata – Representative Director & Chairperson, Forum for Innovative Regenerative Medicine (FIRM), Japan
Dr Ken-ichiro Hata, representative director and chairperson of Japan’s Forum for Innovative Regenerative Medicine (FIRM) outlines the organisation’s mandate, how Japan has been able to cultivate one of the world’s most mature regenerative medicine ecosystems, and highlights key challenges including regulatory misalignment across Asia and the need for better manufacturing and commercialisation models. We are confident that 2020 and…
Top 5 RNA-Based Biopharma Companies
Below we present a list of the top 5 public biopharma companies that focus on developing RNA-based therapies. RNA…
Cell & Gene Therapy / Reconsidering Manufacturing
Advances in cell and gene therapies (CGT) are credited with thoroughly transforming medicinal science and creating…
Cell & Gene Therapy / Funding the Boom
The ascent of cell and gene therapies (CGT) is commonly regarded as one of the momentous turning points in the…
USA / Paying for Cell & Gene Therapy: Is the Future Already Here?
Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced,…
RWE / Unlocking the Full Potential of Cell & Gene
Emerging cell and gene therapies herald immense clinical value for patients, society, and healthcare systems:…
US Medicare Vows to Increase Payments for Cell & Gene Therapy
Medicare, a national health insurance program in the United States covering Americans aged 65 and older as well as…
Cell & Gene Therapy / Funding the Boom
The ascent of cell and gene therapies (CGT) is commonly regarded as one of the momentous turning points in the…
China / Four Cell & Gene Companies to Know
While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene…
Tackling the Talent Gap in Cell & Gene Therapy
Rare diseases and cell and gene therapy executive recruitment specialist Steve Smith outlines six key strategies…
Cell & Gene Therapy / Curing the Incurable: A New Age for Pharmacovigilance
Bayer’s Michael Levy casts his eye over the implications of the advent of cell and gene therapies on…
Cell & Gene Therapy / Embryonic Gene Editing: How Far is Too Far to Find a Treatment for Your Child?
Rare disease patient advocate Monica Weldon outlines some of the ethical conundrums around embryonic gene editing.…
Bayer: Betting Big on Cell & Gene Therapy
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as…
Cell & Gene Therapy / Collaborative Spirit
One of the more intriguing aspects about the new wave of cell and gene therapies (CGT) coming onstream is that they…
Cell & Gene Therapy / Finding the Funding in France
France – one of the most influential countries in the development of gene therapy– still stands as a global…
China / Edigene CEO on Gene Editing Biotech’s Ambitious Expansion Plans
Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in…